Testing a new companion therapy for LAMA2 muscular dystrophy
Part of Bones, joints & muscles, Genetic & congenital clinical trials.
This study looks at a new protein that might help people with LAMA2-related muscular dystrophy. It uses stored samples to see if the protein could be a useful addition to future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have LAMA2-related muscular dystrophy (LAMA2-RD).
- You must already be part of the LAMA2_GUP24002 study and have signed the consent forms, including the biobank consent.
- You must have given your consent to have your samples stored and used for research.
- You must not have withdrawn your consent or had your diagnosis changed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows people with LAMA2-related muscular dystrophy (a genetic muscle-weakening condition) to learn how it changes over time and find better ways to measure it. By participating, you help researchers identify new disease markers that could improve future treatments.
This study follows people with LAMA2-related muscular dystrophy over time to better understand the condition. It may help with future treatments by learning more about how the disease progresses.
This study follows young children with LAMA2-related congenital muscular dystrophy to learn more about the disease. It does not test a new treatment, so it may help families understand the condition better and prepare for future trials.
This study follows children with LAMA2-related muscular dystrophy to learn how the condition changes over time. It does not test a new treatment, but helps researchers understand the disease better.
This study follows people with LAMA2-related muscular dystrophy or SELENON-related myopathy over 5 years to understand how the condition changes over time. It may help you by tracking your disease progression and contributing to future research.
This study tracks changes in muscle strength and breathing over time in people with certain types of muscular dystrophy. It helps researchers develop better tests to measure how the disease progresses.
Hear when a new LAMA2-MD (Merosin Deficient Congenital Muscular Dystrophy, MDC1A) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.